EndoStim targets $36m IPO

EndoStim hopes to raise $36 million in an initial public offering to support development of a pacemaker-like device to treat severe gastroesophageal reflux disease. EndoStim said it hopes to raise nearly $36 million in an initial public offering, with plans to plow $10 million into clinical studies of its system to treat severe gastroesophageal reflux disease and another $14 million to commercialize the system. EndoStimNews Well, Initial Public Offering (IPO), Otolaryngology/Ear, Nose & Throat (ENT), Wall Street Beatread more
Source: Mass Device - Category: Medical Equipment Authors: Source Type: news